Home Cart Sign in  
Chemical Structure| 943540-74-7 Chemical Structure| 943540-74-7

Structure of JNJ-38877618
CAS No.: 943540-74-7

Chemical Structure| 943540-74-7

JNJ-38877618

CAS No.: 943540-74-7

JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.

Synonyms: JNJ-38877618

4.5 *For Research Use Only !

Cat. No.: A967658 Purity: 99%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łËó¶ÊÊ Inquiry Inquiry
2mg łÍǶÊÊ Inquiry Inquiry
5mg łÿî¶ÊÊ Inquiry Inquiry
10mg łóî¶ÊÊ Inquiry Inquiry
25mg łÇÿʶÊÊ Inquiry Inquiry
50mg łËÿ§¶ÊÊ Inquiry Inquiry
100mg łÍËó¶ÊÊ Inquiry Inquiry
250mg łďËó¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 1mg

    łËó¶ÊÊ

  • 2mg

    łÍǶÊÊ

  • 5mg

    łÿî¶ÊÊ

  • 10mg

    łóî¶ÊÊ

  • 25mg

    łÇÿʶÊÊ

  • 50mg

    łËÿ§¶ÊÊ

  • 100mg

    łÍËó¶ÊÊ

  • 250mg

    łďËó¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JNJ-38877618

CAS No. :943540-74-7
Formula : C20H12F2N6
M.W : 374.35
SMILES Code : FC(C1=CC=C2N=CC=CC2=C1)(F)C3=NN=C4C=CC(C5=CC=NC=C5)=NN43
Synonyms :
JNJ-38877618
MDL No. :MFCD31657377

Safety of JNJ-38877618

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of JNJ-38877618

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01964872 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> Nottingham, United Kingdom Less <<
NCT03138083 Neoplasms Phase 1 Phase 2 Recruiting December 2020 France ... More >> lNSTITUT GUSTAVE ROUSSY Recruiting Villejuif, France, 94805 Contact: Eric Angevin, MD          Netherlands Erasmus Mc Recruiting Rotterdam, Netherlands, 3000 CA Contact: Martijn Lolkema, MD/PhD          Universitair Medisch Centrum Utrecht Recruiting Utrecht, Netherlands, 3584 CX Contact: Filip De Vos, MD          United Kingdom University College London Hospitals Nhs Foundation Trust Recruiting London, United Kingdom, NW1 2BU Contact: Martin Forster, MD          The Christie Nhs Foundation Trust Recruiting Manchester, United Kingdom, M20 4BX Contact: Matthew G Krebs, MD PhD MRCP       Matthew.Krebs@christie.nhs.uk    The Newcastle Upon Tyne Hospitals Nhs Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom, NE7 7DN Contact: Ruth Plummer, MD       Ruth.Plummer@newcastle.ac.uk    University of Oxford, Department of Oncology Recruiting Oxford, United Kingdom, OX3 7LE Contact: Sarah P Blagden, MD    +441865227212    sarah.blagden@oncology.ox.ac.uk Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.67mL

0.53mL

0.27mL

13.36mL

2.67mL

1.34mL

26.71mL

5.34mL

2.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories